With federal politicians talking about ACOA spending another $30-million in the region, AIMS Executive Vice President Charles Cirtwill cautions about throwing money at unproven projects. He believes the extra funding to approve more projects is "problematic".
What works best for consumers when oil prices are falling and electricity rates are increasing. In this story, AIMS Executive Vice President Charles Cirtwill explains that existing policies in Nova Scotia and New Brunswick don't appear to be helping consumers much.
People in New Brunswick are outraged according to the news media about salary bonuses paid to NB Power executives. In this story, AIMS Executive Vice President Charles Cirtwill explains that simple economics could quell the anger.
A study compiled by PricewaterhouseCoopers for the Atlantica BioEnergy Task Force is highlighted.
A report compiled by PricewaterhouseCoopers for the Atlantica Bioenergy Task Force provides 15 recommendations for the forestry industry in Atlantica.
In this op-ed that appeared in the Providence Journal, AIMS President Brian Lee Crowley explains why drug re-importation from Canada will not solve the problem of rising prescription drug costs in the United States. He reminds Americans how the US legal system imposes a huge tax on health care that Canadians do not have to pay.
With oil prices reaching record lows New Brunswickers are wondering why the price of power is not going along with it. AIMS Executive Vice-President Charles Cirtwill explains, the purchasing policy in place for New Brunswick does not work for consumers.
A report on renewable energy technologies released by the Atlantica BioEnergy Task Force gained headlines throughout the region.
As governments propose spending our way out of the economic meltdown, AIMS executive Vice President Charles Cirtwill proposes a less taxing stimulus. This op-ed appeared in newspapers across the country.
In this op-ed that appeared in the Buffalo News, AIMS President Brian Lee Crowley explains why drug re-importation from Canada will not solve the problem of rising prescription drug costs in the United States.